Abstract
We studied clinical effects of meropenem (MEPM, SM-7338), a newly developed parenteral carbapenem β-lactam drug, and following results were obtained.The patients were administered with 16-20 mg/kg of MEPM every 8 hours using 1 hour drip infusion.
1. Clinical effects of MEPM were studied in 10 children with various infectious diseases: 1 with acute bronchitis, and 2 each with acute tonsillitis, acute bronchopneumonia, acute pneumonia, acute urinary infection, and 1 with pertussis pneumonia.The case of pertussis pneumonia later developed bronchiolitis obliterans, hence a steroid and 7-globulin were used. This case was excluded from the clinical evaluation. The efficacy rate was 100% (9/9), and the bacteriological eradication rate was 100% (6/6).
2. No side effects were noted.Clinical laboratory test values were investigated in 10 patients. There was a case of abnormal laboratory test findings with mild elevations of liver functions such as GOT, GPT, and γ-GTP.These abnormalities disappeared in 1 week after the end of therapy.
